EVP-ABD-enhanced MRI to evaluate diffuse liver disease in a rat model.

Autor: Zuo CS; Brain Imaging Center, McLean Hospital, Belmont, Massachusetts 02478, USA. chun@mclean.harvard.edu, Seoane PR, Thomsen M, Gillis T, Meloni E, Harnish PP, Renshaw PF
Jazyk: angličtina
Zdroj: Journal of magnetic resonance imaging : JMRI [J Magn Reson Imaging] 2008 Jun; Vol. 27 (6), pp. 1317-21.
DOI: 10.1002/jmri.21385
Abstrakt: Purpose: To evaluate the feasibility of using manganese-based MR imaging contrast agent EVP-ABD to detect diffuse liver disease in an established rat hepatitis model.
Materials and Methods: Hepatitis was induced by administration of CCl(4) in corn oil vehicle to rats intraperitoneally. MR images were acquired on a 3T scanner using a volume coil approximately 36 hours after the administration of CCl(4). EVP-ABD was administered via a tail vein at a dose of 10 mumol/kg. Multi-TI turboflash images were acquired to evaluate liver R1 (=1/T1) values before and after the EVP-ABD administration. Eighteen rats received various doses of CCl(4) and completed pre- and postcontrast MRI scans and liver histologic evaluation.
Results: The liver R1 after the EVP-ABD administration and the change of the liver R1 before and after the administration, DeltaR1, show significant correlations with the CCl(4) dose. A significant correlation was also found between the histologic scores and the CCl(4) doses despite known variability in the relationship of CCl(4) dose to histology. A significant correlation was found between the histologic score and DeltaR1.
Conclusion: Our results indicate that EVP-ABD-enhanced MRI can detect diffuse liver disease generated by CCl(4) based on the significant correlation between proton R1 in liver following EVP-ABD and the CCl(4) doses as well as the histologic scores.
(2008 Wiley-Liss, Inc)
Databáze: MEDLINE
Externí odkaz: